Use of patient preferences in HTA processes

Learn which role patient preference data can play in HTA processes
No available dates

Online or on location

Danish

2,950 DKK ex VAT

(app. 397 EUR ex VAT)

50% DISCOUNT FOR PUBLIC INSTITUTIONS

Summary

Patient preferences when using medicine is already part of the approval process for new medicines in FDA and EMA and similar procedures are pending within NICE (UK).

At this hot topic seminar, you gain an understanding of how patient perspectives and patient preferences can be used to demonstrate the value of pharmaceutical products. Specifically, you will hear representatives from NICE and the Danish Medicines Council discuss how NICE and The Danish Medicines Council respectively regard such data. 


You will learn from real-life case examples from:

  • Centre for joint decision-making, Lillebælt Hospital
  • Lundbeck
  • NICE

Please note: two lectures are conducted in English, and three lectures will be presented via video link.


KEY WORDS

  • Patient preferences
  • Patient Advocacy
  • Medical Affairs
  • HTA processes
  • NICE

Save information for later
Read more

Course leader(s) & Lecturer(s)

  • Elisabeth Gammelgaard Ludvig
    Course leader
    Owner
    Sundhedsagenda
  • Agathe Le Lay
    Lecturer
    Senior Director and Global Head of Value Evidence
    Lundbeck A/S
  • Jacoline Bouvy
    Lecturer
    Technical Director
    National Institute for Health and Care Excellence (NICE)
  • Karina Dahl Steffensen
    Lecturer
    Professor, Overlæge v. Onkologisk Afdeling og Leder af Center for Fælles Beslutningstagning
    Sygehus Lillebælt
  • Jørgen Schøler Kristensen
    Lecturer
    Formand for Medicinrådet
    Medicinrådet
See all

IS THIS COURSE FOR YOU?

Join this course if you work in a consultant or pharmaceutical company with medical affairs, market access, public affairs, sales & marketing, and patient advocacy.

What you will learn

  1. Understand what patient preferences are, and how they can be generated qualitatively and quantitatively.
  2. Learn how NICE views patient preference data, and how (& if?) The Danish Medicines Council (Medicinrådet) expects to include patient preferences in its future considerations.
  3. Learn how a pharma HQ works with patient preference data in HTA processes.
  4. Understand how Danish HCPs work with patient involvement and patient preferences in joint decision making when choosing treatment type, and how pharma companies can support this work.

What your company will get

  1. An employee who understands patient preferences and how these can be developed.
  2. An employee who understands how patient preferences can be utilised in cross-functional work within a pharma company in drug development, during market access and during launch.

Course information

Prerequisites

Industry knowledge is an advantage.

Examination

There is no examination for this course.

Course leader(s)

Elisabeth Gammelgaard Ludvig
Owner
Sundhedsagenda

Lecturer(s)

Agathe Le Lay
Senior Director and Global Head of Value Evidence
Lundbeck A/S
Jacoline Bouvy
Technical Director
National Institute for Health and Care Excellence (NICE)
Karina Dahl Steffensen
Professor, Overlæge v. Onkologisk Afdeling og Leder af Center for Fælles Beslutningstagning
Sygehus Lillebælt
Jørgen Schøler Kristensen
Formand for Medicinrådet
Medicinrådet

You may also be interested in these courses

Want to know more, or need help?

Contact Client Manager Christina Spangsberg at +45 39 15 09 22